March 3, 2020 - The first 21 SARS-CoV-2 genomes in Austria have now been completed with the contribution of the Biomedical Sequencing Facility of CeMM and MedUni Vienna
SARS CoV-2 Sequencing (created in Unity3D & Octane Renderer for Unity). © Bobby Rajesh Malhotra / CeMM
The first 21 SARS-CoV-2 genomes in Austria have now been completed and published within the scope of the “Mutational Dynamics of SARS-CoV-2” project recently launched by CeMM, the Research Center for Molecular Medicine of the Austrian Academy of Sciences, in close collaboration with the Medical University of Vienna. The project aims at sequencing 1,000 viral genomes obtained from Austrian patient-derived samples, in order to learn more about the molecular understanding of the COVID-19 pandemic and the causative pathogen. The project results will integrate Austrian viral genome data into a global map of SARS-CoV-2 mutations, which will help decipher the mutational dynamics underlying the COVID-19 pandemic.
The COVID-19 outbreak caused by the coronavirus SARS-CoV-2 was declared a pandemic by the World Health Organization (WHO) on 12 March 2020. It is thought to have been transmitted from wild animals to humans in the Chinese province of Hubei already in November 2019. More than 180 countries have been affected, and the COVID-19 disease already caused tens of thousands of deaths.
In an effort to understand the evolution of the virus in the human population, the international research community has started to make the genome sequences of circulating SARS-CoV-2 viruses openly available. No virus genomes of isolates from Austria were reported so far, which presented a considerable gap in the comparative analyses of global transmission routes and of the evolution of this virus. To overcome this, CeMM Principal Investigators Andreas Bergthaler and Christoph Bock launched a collaborative project to elucidate SARS-CoV-2 genomes in Austrian patients using cutting-edge next-generation sequencing techniques and sophisticated computational analyses. “Together with the Center for Virology of the Medical University of Vienna, we developed a rapid-response strategy to generate SARS-CoV-2 whole genome sequences from patients in a time-effective manner. This addresses pertinent questions of national public health concerns and medical research such as tracking of infection chains or time-resolved viral analyses during the different stages of acute respiratory disease caused by SARS-CoV-2”, says Andreas Bergthaler, project co-coordinator and CeMM Principal Investigator.
Initial sequence analysis of the 29,900 nucleotide-long SARS-CoV-2 genomes from Austria revealed on average 6 mutations different to the reference genome isolated in Wuhan, the capital city of the province of Hubei, China in December 2019. The observed number of mutations is in line with other recently reported SARS-CoV-2 genomes. Most of the observed mutations lead to changes in viral proteins, providing evidence for positive selection pressure and evolution within the human population. Assessing the actual impact of these mutations for the virus life cycle and its interactions with both the host and the immune system will be within the scope of future investigations. Ongoing in-depth genomic analyses focus on mutational hotspots, dissect viral diversity between the Austrian strains and the strains from other countries as well as study the mutational dynamics of pandemic SARS-CoV-2.
The project builds on an adapted viral evolution sequencing pipeline, which CeMM researchers had developed and applied to a different RNA virus previously, and puts CeMM and its partners in a unique position for in-depth investigations of the mutational dynamics of SARS-CoV-2. To support the CeMM initiative, the Vienna Science and Technology Fund (WWTF) has awarded the project with €50,000 sequencing funds, as part of the WWTF COVID-19 Rapid Response Funding 2020.
The first milestone of the project has been achieved by today’s release of the first 21 SARS-CoV-2 genome sequences into the public databases of GISAID and nextstrain.org. Together with numerous national partners including Elisabeth Puchhammer-Stöckl and her team from the Center for Virology of the Medical University of Vienna as primary collaborator, the Austrian Agency for Health and Food Safety (AGES) and several universities across Austria, CeMM researchers will continue these efforts to complete the sequencing of 1,000 viral genomes within the next weeks. “Whole genome sequence information of 1,000 patient-derived virus samples will provide a clearer picture of the mutation dynamics of the Austrian strains and enable the comparative analysis of these locally circulating strains in the global context. Thereby, this project will support the ongoing epidemiological and clinical investigations for better molecular insights into the spread of SARS-CoV-2 and how to fight this ravaging viral pandemic”, says Christoph Bock, Head of the Biomedical Sequencing Facility of CeMM and MedUni Vienna and Principal Investigator at CeMM.
The elucidation of the first genomes of circulating SARS-CoV-2 strains in Austria was the first milestone of this inter-disciplinary project. CeMM, the Research Center for Molecular Medicine of the Austrian Academy of Sciences, as the primary medically-oriented research center in the country, is understanding and willing to take up the challenge of assisting the medical world to fight the disease. Together with a growing network of national and international collaboration partners, it will provide valuable scientific data for health care professionals, epidemiologists and public health experts as well as offer the opportunity to molecularly dissect the mutational landscapes and dynamics of this pandemic virus. Such insights will be critical to understand how the virus evolves during human-to-human transmission and to assess its potential to subvert vaccine responses or acquire resistance against future antiviral drugs.
Access SARS-CoV-2 sequencing data:
The sequences and related information are accessible at https://nextstrain.org/ (Real-time tracking of pathogen evolution) and https://www.gisaid.org/ (Global Initiative on Sharing All Influenza Data).
Funding: The project will be co-funded by a COVID19-Rapid Response grant of the Vienna Science and Technology Fund (WWTF), and through in-kind contributions of CeMM, the Austrian Academy of Sciences, the Medical University of Vienna and respective partners.
November 15, 2018 – 6th Vienna Next Generation Sequencing (NGS) Symposium and Workshop
For the sixth time, the Vienna NGS Symposium will bring together the NGS user community in Vienna and Austria, to discuss new developments (e.g. single-cell and long-read technologies, epigenomics, bioinformatics, etc.) and to hear about inspiring success stories using NGS in a broad range of biological applications. As in previous years, attendance is free (no registration fee) and open to all.
The scientific part will comprise a keynote lecture by Robert P. Zinzen (MDC Berlin) about reconstructing whole organisms (and their development) from single-cell RNA sequencing data and presentations by scientists from Vienna who use sequencing technology in new and exciting ways: Elly Tanaka (IMP), Simon Hippenmeyer (ISTA), Stefan Ameres (IMBA), Florian Grebien (LBI-CR), Eleni Tomazou (St. Anna CCRI), Ron Pinhasi (Uni Wien).
The parallel afternoon workshops provides hands-on information on using NGS technology, covering four areas: (1) Getting started with next generation sequencing. (2) Single-cell sequencing technologies. (3) Medical applications of NGS technology. (4) Beyond NGS: Flow and mass cytometry.
The event is jointly organized by Christoph Bock (PI at CeMM & coordinator of the Biomedical Sequencing Facility) and Andreas Sommer (head of the NGS facility at the Vienna Biocenter). Free registration is requested for the afternoon workshop: https://cemm.at/ngs/.
November 13, 2017 – Installation of a NovaSeq 6000 sequencer for cost-effective whole-genome sequencing
An Illumina NovaSeq 6000 sequencer was added to the portfolio of the Biomedical Sequencing Facility and will support large-scale sequencing applications including large-scale genome and epigenome sequencing.
Illumina’s new NovaSeq 6000 platform provides the highest sequencing throughput as well as full flexibility for a broad range of applications, while providing a price per megabase that is substantially lower than on the HiSeq 3000/4000, NextSeq, or MiSeq platforms. The NovaSeq 6000 sequencer makes it possible to sequence several dozen human whole genomes at deep coverage in a single run.
The Biomedical Sequencing Facility has recently installed a NovaSeq 6000 sequencer, adding to its machine park of HiSeq 3000/4000 (2x), NextSeq, and MiSeq sequencers. After a series of successful assay validations, this machine is now avaliable for those projects and protocols that benefit from the dramatically increased sequencing throughput. Please contact firstname.lastname@example.org to discuss how your project might benefit from the throughput that the NovaSeq 6000 platfrom provides to NGS users.
Strictly necessary cookies guarantee functions without which this website would not function as intended. As a result these cookies cannot be deactivated. These cookies are used exclusively by this website and are therefore first party cookies. This means that all information stored in the cookies will be returned to this website.
Functional cookies enable this website to provide you with certain functions and to store information already provided (such as registered name or language selection) in order to offer you improved and more personalized functions.
Performance cookies gather information on how a web page is used. We use them to better understand how our web pages are used in order to improve their appeal, content and functionality.
Marketing / Third Party Cookies originate from external advertising companies (among others) and are used to gather information about the websites visited by you, in order to e.g. create targeted advertising for you.